JP2024023232A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024023232A5 JP2024023232A5 JP2023189072A JP2023189072A JP2024023232A5 JP 2024023232 A5 JP2024023232 A5 JP 2024023232A5 JP 2023189072 A JP2023189072 A JP 2023189072A JP 2023189072 A JP2023189072 A JP 2023189072A JP 2024023232 A5 JP2024023232 A5 JP 2024023232A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- polypeptide
- identity
- nucleic acid
- car
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025184908A JP2026031977A (ja) | 2018-06-04 | 2025-10-31 | Ｍｕｃ１６特異的キメラ抗原受容体およびそれらの使用 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862680297P | 2018-06-04 | 2018-06-04 | |
| US62/680,297 | 2018-06-04 | ||
| PCT/US2019/035384 WO2019236577A2 (en) | 2018-06-04 | 2019-06-04 | Muc16 specific chimeric antigen receptors and uses thereof |
| JP2020567215A JP2021525534A (ja) | 2018-06-04 | 2019-06-04 | Ｍｕｃ１６特異的キメラ抗原受容体およびそれらの使用 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020567215A Division JP2021525534A (ja) | 2018-06-04 | 2019-06-04 | Ｍｕｃ１６特異的キメラ抗原受容体およびそれらの使用 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025184908A Division JP2026031977A (ja) | 2018-06-04 | 2025-10-31 | Ｍｕｃ１６特異的キメラ抗原受容体およびそれらの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024023232A JP2024023232A (ja) | 2024-02-21 |
| JP2024023232A5 true JP2024023232A5 (enExample) | 2024-10-16 |
| JP7827673B2 JP7827673B2 (ja) | 2026-03-10 |
Family
ID=68764543
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020567215A Pending JP2021525534A (ja) | 2018-06-04 | 2019-06-04 | Ｍｕｃ１６特異的キメラ抗原受容体およびそれらの使用 |
| JP2023189072A Active JP7827673B2 (ja) | 2018-06-04 | 2023-11-06 | Ｍｕｃ１６特異的キメラ抗原受容体およびそれらの使用 |
| JP2025184908A Withdrawn JP2026031977A (ja) | 2018-06-04 | 2025-10-31 | Ｍｕｃ１６特異的キメラ抗原受容体およびそれらの使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020567215A Pending JP2021525534A (ja) | 2018-06-04 | 2019-06-04 | Ｍｕｃ１６特異的キメラ抗原受容体およびそれらの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025184908A Withdrawn JP2026031977A (ja) | 2018-06-04 | 2025-10-31 | Ｍｕｃ１６特異的キメラ抗原受容体およびそれらの使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US11319380B2 (enExample) |
| EP (1) | EP3802615A4 (enExample) |
| JP (3) | JP2021525534A (enExample) |
| KR (1) | KR20210021493A (enExample) |
| CN (2) | CN112533957B (enExample) |
| AU (1) | AU2019282620B2 (enExample) |
| CA (1) | CA3101641A1 (enExample) |
| IL (1) | IL278976A (enExample) |
| SG (1) | SG11202011895VA (enExample) |
| WO (1) | WO2019236577A2 (enExample) |
| ZA (3) | ZA202008065B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| IL273961B2 (en) * | 2017-10-18 | 2025-04-01 | Precigen Inc | Polypeptide compositions containing spacers |
| WO2020088631A1 (en) * | 2018-11-01 | 2020-05-07 | Gracell Biotechnologies (Shanghai) Co., Ltd. | Compositions and methods for t cell engineering |
| MX2022002747A (es) | 2019-09-10 | 2022-04-06 | Obsidian Therapeutics Inc | Proteinas de fusion de ca2-il15 para regulacion ajustable. |
| EP4170020A4 (en) * | 2020-06-17 | 2025-01-22 | Kyoto University | IMMUNOCOMPETENT CELLS WITH CHIMERIC ANTIGEN RECEPTOR EXPRESSION |
| US12404315B2 (en) * | 2020-12-21 | 2025-09-02 | Allogene Therapeutics, Inc. | Protease-activating CD45-gate CAR |
| CN116648457A (zh) * | 2020-12-31 | 2023-08-25 | 亘喜生物科技（上海）有限公司 | 膜融合蛋白及其在免疫细胞中的应用 |
| CA3205291A1 (en) * | 2021-01-19 | 2022-07-28 | Rachel BURGA | Tumor-infiltrating lymphocytes with membrane bound interleukin 15 and uses thereof |
| KR20230147619A (ko) * | 2021-02-26 | 2023-10-23 | 난징 레전드 바이오테크 씨오., 엘티디. | 외인적으로 도입된 사이토카인을 발현하는 조작된 면역이펙터 세포 |
| US20250145950A1 (en) * | 2022-02-01 | 2025-05-08 | Alaunos Therapeutics, Inc. | Methods for Activation and Expansion of T Cells |
| CN115819613B (zh) * | 2022-05-10 | 2023-10-20 | 四川大学华西医院 | 基于msln前体蛋白构建的嵌合抗原受体免疫细胞制备及其应用 |
| CN116196402A (zh) * | 2022-11-01 | 2023-06-02 | 山东大学齐鲁医院 | 表达双特异性抗体的溶瘤腺病毒联合cart在肿瘤治疗中的应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2491017A1 (en) | 2002-07-03 | 2004-01-15 | Immunogen, Inc. | Antibodies to non-shed muc1 and muc16, and uses thereof |
| BRPI0613382A8 (pt) | 2005-06-20 | 2018-01-02 | Genentech Inc | anticorpos isolados, anticorpo monoclonal, célula de hibridoma, método de identificação, método de inibição do crescimento de uma célula, método de tratamento terapêutico, método de determinação da presença de uma proteína, métodos de diagnósticos da presença de tumor |
| TW200902554A (en) | 2007-05-08 | 2009-01-16 | Genentech Inc | Cysteine engineered anti-MUC16 antibodies and antibody drug conjugates |
| WO2009088105A1 (en) | 2008-01-11 | 2009-07-16 | Gene Techno Science Co., Ltd. | HUMANIZED ANTI-α9 INTEGRIN ANTIBODIES AND THE USES THEREOF |
| ES2717629T3 (es) * | 2009-11-03 | 2019-06-24 | Hope City | Receptor del factor de crecimiento epidérmico truncado (EGFRt) para selección de células T transducidas |
| US9169328B2 (en) * | 2010-03-26 | 2015-10-27 | Memorial Sloan Kettering Cancer Center | Antibodies to MUC16 and methods of use thereof |
| WO2014165707A2 (en) | 2013-04-03 | 2014-10-09 | Memorial Sloan-Kettering Cancer Center | Effective generation of tumor-targeted t-cells derived from pluripotent stem cells |
| EP3974520A1 (en) * | 2013-05-14 | 2022-03-30 | Board of Regents, The University of Texas System | Human application of engineered chimeric antigen receptor (car) t-cells |
| CN106795221B (zh) * | 2014-04-03 | 2022-06-07 | 塞勒克提斯公司 | 用于癌症免疫治疗的cd33特异性嵌合抗原受体 |
| MY181834A (en) * | 2014-07-21 | 2021-01-08 | Novartis Ag | Treatment of cancer using humanized anti-bcma chimeric antigen receptor |
| CN107530427A (zh) | 2015-03-27 | 2018-01-02 | 南加利福尼亚大学 | 针对用于实体肿瘤的治疗的lhr的car t细胞疗法 |
| US10017577B2 (en) | 2015-06-15 | 2018-07-10 | Genentech, Inc. | Antibodies and immunoconjugates |
| US11242375B2 (en) | 2015-09-04 | 2022-02-08 | Memorial Sloan Kettering Cancer Center | Immune cell compositions and methods of use |
| WO2017172981A2 (en) * | 2016-03-29 | 2017-10-05 | University Of Southern California | Chimeric antigen receptors targeting cancer |
| EP3468994A1 (en) | 2016-06-08 | 2019-04-17 | Intrexon Corporation | Cd33 specific chimeric antigen receptors |
| JP2019524706A (ja) * | 2016-07-08 | 2019-09-05 | ジェネンテック， インコーポレイテッド | Ｍｕｃ１６陽性癌治療の応答性を評価するためのヒト精巣上体タンパク質４（ｈｅ４）の使用 |
| CA3031955A1 (en) | 2016-07-29 | 2018-02-01 | Juno Therapeutics, Inc. | Immunomodulatory polypeptides and related compositions and methods |
| EP3522933B1 (en) * | 2016-10-05 | 2021-12-15 | F. Hoffmann-La Roche AG | Methods for preparing antibody drug conjugates |
| CN107557336B (zh) * | 2017-09-15 | 2020-02-14 | 山东兴瑞生物科技有限公司 | 一种抗muc16安全型嵌合抗原受体修饰的免疫细胞及其应用 |
-
2019
- 2019-06-04 CN CN201980052129.8A patent/CN112533957B/zh active Active
- 2019-06-04 CA CA3101641A patent/CA3101641A1/en active Pending
- 2019-06-04 AU AU2019282620A patent/AU2019282620B2/en active Active
- 2019-06-04 JP JP2020567215A patent/JP2021525534A/ja active Pending
- 2019-06-04 US US16/431,193 patent/US11319380B2/en active Active
- 2019-06-04 EP EP19815389.2A patent/EP3802615A4/en active Pending
- 2019-06-04 KR KR1020207038033A patent/KR20210021493A/ko active Pending
- 2019-06-04 SG SG11202011895VA patent/SG11202011895VA/en unknown
- 2019-06-04 WO PCT/US2019/035384 patent/WO2019236577A2/en not_active Ceased
- 2019-06-04 CN CN202610008767.1A patent/CN121852427A/zh active Pending
-
2020
- 2020-11-25 IL IL278976A patent/IL278976A/en unknown
- 2020-12-23 ZA ZA2020/08065A patent/ZA202008065B/en unknown
-
2021
- 2021-12-22 ZA ZA2021/10780A patent/ZA202110780B/en unknown
-
2022
- 2022-02-04 US US17/650,018 patent/US11981746B2/en active Active
- 2022-02-04 US US17/650,025 patent/US11976134B2/en active Active
-
2023
- 2023-11-06 JP JP2023189072A patent/JP7827673B2/ja active Active
- 2023-12-19 ZA ZA2023/11718A patent/ZA202311718B/en unknown
-
2024
- 2024-04-05 US US18/628,575 patent/US20240368305A1/en active Pending
-
2025
- 2025-10-31 JP JP2025184908A patent/JP2026031977A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12371489B2 (en) | Car based immunotherapy | |
| US9868961B2 (en) | Methods and compositions for localized secretion of anti-CTLA-4 antibodies | |
| JP2024138280A5 (enExample) | ||
| JP7198670B2 (ja) | 免疫調整性ｉｌ２ｒ融合タンパク質およびその使用 | |
| EP3599251A1 (en) | Construction of chimeric antigen receptor targeting cd20 antigen and activity identification of engineered t cells thereof | |
| JP7636650B2 (ja) | 二量体形成剤調節性免疫受容体複合体 | |
| JP7833569B2 (ja) | Ｂｃｍａ－ｃｄ１９を標的とする二重特異性キメラ抗原受容体およびその用途 | |
| JP2022531222A5 (enExample) | ||
| JP2021525534A5 (enExample) | ||
| KR20180057723A (ko) | 항-cd30 키메라성 항원 수용체 | |
| CN107936120B (zh) | Cd19靶向性的嵌合抗原受体及其制法和应用 | |
| JP7431735B2 (ja) | Ｄａｒｉｃインターロイキン受容体 | |
| AU2018385694B2 (en) | NKG2D DARIC receptors | |
| CN110257338A (zh) | 嵌合细胞因子受体 | |
| JP2026506591A (ja) | 天然タンパク質ｔｓｈを抗原結合部位とした、ｔｓｈｒを標的とするｃａｒ－ｔ細胞の構築 | |
| WO2023093888A1 (zh) | 基于efna1构建的嵌合抗原受体免疫细胞制备及其应用 | |
| KR20240111378A (ko) | Nkg2d 키메라 수용체, 이를 발현하는 형질전환 세포 및 이의 항암 용도 | |
| CN109593137B (zh) | 抗cd20抗体的新型cd20-car载体的构建及应用 | |
| HK40123857A (en) | Bispecific chimeric antigen receptor targeting bcma-cd19 and application thereof | |
| WO2024179518A1 (zh) | 具有优化的itam结构域及cd28与4-1bb双共刺激分子的双靶点car-t | |
| WO2024190856A1 (ja) | 抗ｂｃｍａ抗体およびキメラ抗原受容体 | |
| HK40100191A (zh) | 用於同种异体细胞治疗的通用嵌合抗原受体表达免疫细胞 | |
| CN110938641A (zh) | 靶向april的嵌合抗原受体及其用途 |